FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Börse Stuttgart 12:18:33 05/06/2024 am IST | ||
| 3.36 EUR | -19.62% |
|
| Current month | -23.11% | ||
| 1 month | -69.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 3.36 | -19.62% |
| 03/24/03 | 4.18 | -4.35% |
| 31/24/31 | 4.37 | -6.02% |
| 30/24/30 | 4.65 | +0.87% |
| 29/24/29 | 4.61 | +2.44% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 12:18 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG1SF5 |
| ISIN | DE000MG1SF58 |
| Date issued | 05/04/2024 |
| Strike | 1,053 kr |
| Maturity | Unlimited |
| Parity | 4.03 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.72 € |
|---|---|
| Lowest since issue | 3.36 € |
| Spread | 0.16 € |
| Spread % | 5.23% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Certificates
- Certificat
